Skip to content
10-Q

Quarterly Report

BioRestorative Therapies, Inc. BRTX

0001493152-25-021993

← back to feed
Filed
Nov 12, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2025 · Nov 11, 2025 8.88M sh
Shares Diluted Q3 2025 · Sep 30, 2025 9.12M sh
Shares Diluted Q3 2025 · Sep 30, 2025 8.74M sh
Shares Diluted Q3 2025 · Sep 30, 2024 8.12M sh
Shares Diluted Q3 2025 · Sep 30, 2024 7.64M sh
Stock Repurchased Q3 2025 · Sep 30, 2025 $0
Capex Q3 2025 · Sep 30, 2025 $36.4K
Capex Q3 2025 · Sep 30, 2024 $93.76K
Operating Cash Flow Q3 2025 · Sep 30, 2025 −$8.37M
Operating Cash Flow Q3 2025 · Sep 30, 2024 −$5.88M
Cash And Equivalents Q3 2025 · Sep 30, 2025 $602.44K
Cash And Equivalents Q3 2025 · Dec 31, 2024 $547.89K
Stockholders Equity Q3 2025 · Sep 30, 2025 $2.21M
Stockholders Equity Q3 2025 · Jun 30, 2025 $4.85M
Stockholders Equity Q3 2025 · Mar 31, 2025 $6.14M
Stockholders Equity Q3 2025 · Dec 31, 2024 $8.53M
Stockholders Equity Q3 2025 · Sep 30, 2024 $9.99M
Stockholders Equity Q3 2025 · Jun 30, 2024 $10.8M
Stockholders Equity Q3 2025 · Mar 31, 2024 $14.5M
Stockholders Equity Q3 2025 · Dec 31, 2023 $10M
Current Liabilities Q3 2025 · Sep 30, 2025 $3.44M
Current Liabilities Q3 2025 · Dec 31, 2024 $3.75M
Current Assets Q3 2025 · Sep 30, 2025 $4.71M
Current Assets Q3 2025 · Dec 31, 2024 $11.14M
Total Assets Q3 2025 · Sep 30, 2025 $5.64M
Total Assets Q3 2025 · Dec 31, 2024 $12.28M
Eps Diluted Q3 2025 · Sep 30, 2025 −$0.33
Eps Diluted Q3 2025 · Sep 30, 2025 −$1.26
Eps Diluted Q3 2025 · Sep 30, 2024 −$0.13
Eps Diluted Q3 2025 · Sep 30, 2024 −$0.96
Eps Basic Q3 2025 · Sep 30, 2025 −$0.33
Eps Basic Q3 2025 · Sep 30, 2025 −$1.26
Eps Basic Q3 2025 · Sep 30, 2024 −$0.13
Eps Basic Q3 2025 · Sep 30, 2024 −$0.96
Sga Expense Q3 2025 · Sep 30, 2025 $1.12M
Sga Expense Q3 2025 · Sep 30, 2025 $4.67M
Sga Expense restated Q3 2025 · Sep 30, 2024 $1.05M
Sga Expense restated Q3 2025 · Sep 30, 2024 $4.19M
Rd Expense Q3 2025 · Sep 30, 2025 $2.59M
Rd Expense Q3 2025 · Sep 30, 2025 $7.47M
Rd Expense restated Q3 2025 · Sep 30, 2024 $1.45M
Rd Expense restated Q3 2025 · Sep 30, 2024 $5M
Net Income Q3 2025 · Sep 30, 2025 −$3.04M
Net Income Q3 2025 · Sep 30, 2025 −$11.03M
Net Income Q3 2025 · Jun 30, 2025 −$2.66M
Net Income Q3 2025 · Mar 31, 2025 −$5.34M
Net Income Q3 2025 · Sep 30, 2024 −$1.09M
Net Income Q3 2025 · Sep 30, 2024 −$7.34M
Net Income Q3 2025 · Jun 30, 2024 −$4.03M
Net Income Q3 2025 · Mar 31, 2024 −$2.22M
Operating Income Q3 2025 · Sep 30, 2025 −$3.71M
Operating Income Q3 2025 · Sep 30, 2025 −$11.82M
Operating Income Q3 2025 · Sep 30, 2024 −$2.29M
Operating Income Q3 2025 · Sep 30, 2024 −$8.87M
Gross Profit Q3 2025 · Sep 30, 2025 $1.23K
Gross Profit Q3 2025 · Sep 30, 2025 $317.89K
Gross Profit Q3 2025 · Sep 30, 2024 $215.36K
Gross Profit Q3 2025 · Sep 30, 2024 $332.97K
Cost Of Revenue Q3 2025 · Sep 30, 2025 $10.57K
Cost Of Revenue Q3 2025 · Sep 30, 2025 $22.21K
Cost Of Revenue Q3 2025 · Sep 30, 2024 $18.24K
Cost Of Revenue Q3 2025 · Sep 30, 2024 $24.73K
Revenue Q3 2025 · Sep 30, 2025 $11.8K
Revenue Q3 2025 · Sep 30, 2025 $340.1K
Revenue Q3 2025 · Sep 30, 2024 $233.6K
Revenue Q3 2025 · Sep 30, 2024 $357.7K